Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
57
resultados
Última actualización
27/07/2026 [06:45:00]
Resumen de: WO2026152242A1
The present invention relates to a polysaccharide with cytotoxic activity against human colon, human lung, human melanoma and murine leukaemia tumour cells, as well as antioxidant and healing activity. The invention also relates to a method for producing the polysaccharide, its uses and applications, particularly via drugs for treating cancer and/or antioxidant and healing compositions. The polysaccharide of the present invention can be produced from biomass, particularly from fungi, and preferably from the fungus Bovistella utriformis.
Resumen de: US20260209308A1
0000 Provided herein is a method of treating a subject who has multiple myeloma. A single infusion of chimeric antigen receptor (CAR)-T cells comprising an anti-BCMA CAR comprising a polypeptide is administered to the subject. In certain embodiments, the dose of CAR-T cells administered to the subject is from 1.0×10<5 >to 5.0×10<6 >of CAR-T cells per kilogram of the subject's mass. The method of treatment is effective in obtaining and maintaining minimal residual disease negativity status, as well as other beneficial clinical outcomes related to efficacy and safety.
Resumen de: US20260207742A1
0000 Provided is a pharmaceutical combination comprising an antibody specific for CD19 and a natural killer cell, and a treatment method using the same. Such a pharmaceutical combination is capable of exhibiting synergistic therapeutic effects on a malignant tumor of B-cell origin such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and/or acute lymphoblastic leukemia.
Resumen de: US20260207757A1
0000 Provided are methods of treating myelodysplastic syndrome (MDS), oligoblastic acute myelogenous leukemia (O-AML), or chronic myelomonocytic leukemia (CMML) using 765IGF-MTX and other IGF-receptor-targeted agents, and formulations for delivering 765IGF-MTX and other IGF-receptor-targeted agents to patients. Also provided are pharmaceutical compositions for use in treating MDS, O-AML, and CMML.
Resumen de: US20260207557A1
This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
Resumen de: US20260207738A1
Disclosed herein are compositions and kits which comprise anti-CD38 antibodies and carfilzomib compounds. Also disclosed are methods for treating cancers, such as multiple myeloma, in subjects with the compositions and kits.
Resumen de: WO2026154051A1
The present invention relates to gliptins, the inhibitors of dipeptidyl peptidase 4, also known as DPP-4 inhibitors, for use in the treatment and/or prevention of diseases in a human subject. The present invention relates to a pharmaceutical composition comprising a compound selected from the group consisting of gliptins, pharmaceutically acceptable salts thereof and hydrates thereof, for use in a therapeutic or prophylactic method of treating a MALT-1 involving disease in a subject, preferably selected from allergic inflammatory disease, an autoimmune disease, multiple myeloma and glioma, in a human subject in need thereof. The present invention also relates to the use of gliptins as an allosteric MALT1 inhibitor for use in a method of treating a MALT-1 involving disease in a subject, preferably selected from an allergic inflammation disease, multiple sclerosis, multiple myeloma and glioma. The present invention is also directed to the field of personalized cancer care and treatment.
Resumen de: US20260207710A1
0000 Disclosed herein are methods for treating a cancer in a subject in need thereof, comprising administering (a) an IL-2 conjugate, and (b) a chimeric antigen receptor (CAR) therapy. Also disclosed herein are methods for treating diffuse large B-cell lymphoma (DLBCL) in a subject in need thereof, comprising administering an IL-2 conjugate.
Resumen de: US20260209356A1
0000 The present invention concerns a vector including the cassette coding for B7-H3 CAR gene obtained using the single chains variable fragments (scFv) of the monoclonal IgG antibody NE97, a method for the production thereof and B7-H3 CAR genetically modified effector cells (such as T cells or innate cells such as NK and NK-T cells) for the treatment of CD276 (B7-H3) positive tumors such as lymphoid malignancies, leukemia and solid tumors such as CNS tumors, extra-cranial and intracranial tumors and autoimmune diseases.
Resumen de: US20260209298A1
0000 The present invention is to confirm that PLK1 induces tumor formation and cancer metastasis through IGFBP5 phosphorylation, and provide an IGFBP5 mutant in which a region phosphorylated by PLK1 is mutated and a vector expressing same. The IGFBP5 mutant of the present invention maintains a binding ability to PLK1, and thus binds to PLK1 overexpressed competitively with wild-type IGFBP5 in cancer cells, thereby making it possible to inhibit tumor formation and cancer metastasis, and the provision of a vector expressing the mutant in cancer cells can inhibit cancer mobility and invasiveness and inhibit tumor formation. The mutant of the present invention is safe because it does not affect the inherent function of IGFBP5 in normal cells, and thus can be useful in the treatment of various diseases caused by abnormal cell growth, especially degenerative diseases such as primary and metastatic solid cancer and leukemia.
Resumen de: US20260209271A1
Disclosed herein is a series of helical sulfono-γ-AApeptides that mimic the binding mode of the α-helical HD2 domain of B-Cell Lymphoma 9 (BCL9). As disclosed herein, sulfono-γ-AApeptides can structurally and functionally mimic the α-helical domain of BCL9, and selectively disrupt β-catenin/BCL9 PPIs with even higher potency. More intriguingly, these sulfono-γ-AApeptides can enter cancer cells, bind with β-catenin and disrupt β-catenin/BCL PPI, and exhibit excellent cellular activity, which is much more potent than the BCL9 peptide. Furthermore, enzymatic stability studies demonstrated the remarkable stability of the helical sulfono-γ-AApeptides, with no degradation in the presence of pronase for 24 h, augmenting their biological potential.
Resumen de: AU2025218081A1
Provided herein are methods of treating a subject who has multiple myeloma and has received an initial therapy, including a stem cell transplantation. Infusions of chimeric antigen receptor (CAR)-T cells comprising a BCMA CAR comprising a polypeptide are administered to the subject. In certain embodiments, the dose of CAR-T cells administered to the subject is from 1.0 x 105 to 5.0 x 106 of CAR-T cells per kilogram of the subject's mass. The method of treatment is effective in obtaining and maintaining minimal residual disease negativity status, as well as other beneficial clinical outcomes related to efficacy and safety.
Resumen de: US20260199361A1
0000 The present disclosure provides compositions comprising Pralatrexate for subcutaneous administration. The present disclosure also provides methods of administering the compositions comprising Pralatrexate, as disclosed herein, for the treatment of disease (e.g., lymphoma).
Resumen de: US20260201032A1
The present invention relates to a CD229 and a BCMA targeting moiety, wherein the CD229 targeting moiety is an antibody, F(ab′)2, Fab, scFab or scFv. The present invention further provides CARs, nucleic acid, cells, pharmaceutical compositions and kits comprising the CD229 and BCMA targeting moiety. Methods of treatment of a CD229-positive cancer, preferably Multiple Myeloma, are also provided.
Resumen de: US20260199469A1
0000 The present invention refers to a bispecific in tandem receptor CAR, named RfuCAR, which includes a scFv that recognizes and ligates surface molecules on tumoral cells (CD33, CD123 or another tumoral target) and the IL-1 receptor type 2 (IL-1R2). According to this, the IL1-R2 was chosen as the ideal receptor to compose the RfuCAR construction, being able to capture the IL-1B with high affinity and specificity. These proprieties indicate it as a good candidate to reduce the neurotoxicity and CRS effects of CAR-T therapies. Additionally, the present invention deals with a method for modulating the tumoral microenvironment, for example, in case of acute myeloid leukemia, or other cancer type like but not restricted to acute lymbloblastic leukemia, pancreatic, lung and ovarian cancer.
Resumen de: US20260200878A1
The objective of the present invention is to provide a novel 2-((trans-4-(4-aryloxy)cyclohexyl)amino)quinazolinone derivative which exhibits anti-cancer activity through elF2α phosphorylation efficacy, wherein the novel synthesized derivative exhibits an eIF2α phosphorylation effect and cancer cell proliferation inhibitory activity in vitro, and thus can be used as a metabolic anti-cancer drug in pharmaceutical and health functional food compositions for preventing and ameliorating leukemia and other rare cancers such as breast cancer, brain tumor, and sarcoma.
Resumen de: US20260199335A1
0000 The present disclosure relates to compounds of Formula 1 and pharmaceutical compositions thereof for the treatment of cancer in a subject having a mutant form of NPM1, DNMT3A, RAS, or a combination thereof, or for specific treatments of subjects with relapsed or treatment-refractory (R/R) acute myeloid leukemia (AML).
Resumen de: US20260199347A1
0000 Therapeutic combinations of a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the γ- and δ-isoforms and selective for both γ- and δ-isoforms (PI3K-γ,δ, PI3K-γ, and PI3K-δ), a Janus kinase-2 (JAK-2) inhibitor, a Bruton's tyrosine kinase (BTK) inhibitor, and/or a B-cell lymphoma-2 (BCL-2) inhibitor are described. In some embodiments, the invention provides therapeutic combinations of a PI3K-δ inhibitor and a BTK inhibitor, a JAK-2 and a BTK inhibitor, and a BCL-2 and BTK inhibitor.
Resumen de: US20260201476A1
The present disclosure provides methods of treating acute myeloid leukemia (AML) and methods of determining responsiveness to AML treatment regimens, including regimens comprising the administration of a BCL-2 inhibitor, a hypomethylating agent, a CD70-targeting agent, or any combination thereof, the methods comprising identifying the presence or absence of one or more biomarkers described herein.
Resumen de: US20260199343A1
The present disclosure provides methods of administering belumosudil to patients with multiple myeloma.
Resumen de: US20260199514A1
A nanoparticle and methods of using the same wherein the nanoparticle includes a prodrug comprising a targeting moiety-lipid conjugate, a polyethylene glycol-lipid conjugate, a sterol, a bulk lipid, and a drug-lipid conjugate, wherein a chemical linker group is positioned between the drug moiety and the lipid moiety of the drug-lipid conjugate. The nanoparticle can be used to treat cancer, for example, multiple myeloma.
Resumen de: AU2025216013A1
Provided herein are methods of treating acute leukemia, such as acute myeloid leukemia (AML), in an individual, comprising administering to the individual a menin inhibitor and a standard-of-care therapy.
Resumen de: US20260199359A1
The present disclosure relates to topical formulations and methods of treating skin diseases using topical formulations comprising a JAK ½ inhibitor, which is ruxolitinib, or a pharmaceutically acceptable salt thereof, and an organic amine pH adjusting agent. The skin diseases for treatment include, but are not limited to, psoriasis, atopic dermatitis, alopecia, vitiligo, Reiter's syndrome, Pityriasis rubra pilaris, epidermolysis bullosa simplex, palmoplantar keratoderma, pachyonychia congenita, steatocystoma multiplex, cutaneous lichen planus, cutaneous T-cell lymphoma, hidradenitis suppurativa, contact dermatitis, ichthyosis, and a disorder of keratinization. The organic amine pH adjusting agent is a tertiary amine or an alkanol amine.
Resumen de: AU2024392986A1
Provided herein are methods and uses for treating multiple myeloma (such as Newly Diagnosed Multiple Myeloma) in a patient in need thereof. The methods comprise administering to the patient an anti-CD38 antibody, bortezomib, lenalidomide, and dexamethasone.
Nº publicación: WO2026151712A1 16/07/2026
Solicitante:
NORTHWESTERN UNIV [US]
NORTHWESTERN UNIVERSITY
Resumen de: WO2026151712A1
The present disclosure relates generally to lymphoma fusion and translocation proteins, and methods of use of the proteins in T cell therapy.
BOPI
Sede Electrónica
